A study by the University of New South Wales (UNSW) has revealed that changes to Australia’s Pharmaceutical Benefits Scheme (PBS) have led to a significant drop in subsidised opioid use. The policy amendments in June 2020, including restrictions on repeat prescriptions and introduction of half-pack sizes, resulted in a 4% overall decline in opioid use. However, the use of tapentadol, a newer opioid, increased. Researchers suspect the Covid-19 pandemic may have influenced this rise.
FDA approves breast cancer drug
The FDA has approved Eli Lilly’s imlunestrant, an oral estrogen receptor antagonist, for the treatment of adults with estrogen receptor positive, HER2-negative, ESR1-mutated advanced or
